Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report

被引：2

作者：

Khatib, Mohamad Y. ^{[1
]}

Allafi, Solaiman M. ^{[1
]}

Nashwan, Abdulqadir J. ^{[2
,3
]}

机构：

[1] Hamad Med Corp HMC, Hazm Mebaireek Gen Hosp HMGH, Med Intens Care Dept, Doha, Qatar

[2] Hamad Med Corp HMC, Hazm Mebaireek Gen Hosp HMGH, Educ & Practice Dev, POB 3050, Doha, Qatar

[3] Univ Calgary Qatar UCQ, Doha, Qatar

来源：

CLINICAL CASE REPORTS | 2021年 / 9卷 / 02期

关键词：

human antichimeric antibodies; immunosuppressant; pemphigus vulgaris; rituximab; serum sickness; EFFICACY; GRANULOMATOSIS; POLYANGIITIS; ANTIBODIES; SAFETY;

D O I：

10.1002/ccr3.3642

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Serum sickness, a reaction presenting with a classic triad (fever, rash, myalgia/arthralgia), is considered as a rare adverse event following monoclonal antibodies and specifically following treatment with rituximab. This report describes a case of serum sickness in a newly treated young male patient with rituximab for pemphigus vulgaris.

引用

页码：751 / 754

页数：4

共 26 条

[1] Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP) [J].

Ahmad, A ;

Aggarwal, A ;

Sharma, D ;

Dave, HP ;

Kinsella, V ;

Rick, ME ;

Schechter, GP .

AMERICAN JOURNAL OF HEMATOLOGY, 2004, 77 (02) :171-176

[2]

Awal G., 2018, JEWDS, V15, P54

[3] Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study [J].

Bayer, Guillaume ;

Agier, Marie-Sara ;

Lioger, Bertrand ;

Lepelley, Marion ;

Zenut, Marie ;

Lanoue, Mary-Christine ;

Maillot, Francois ;

Jonville-Bera, Annie-Pierre .

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 67 :59-64

[4] Rituximab: clinical development and future directions [J].

Cheson, BD .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (01) :97-110

[5] Managing premedications and the risk for reactions to infusional monoclonal antibody therapy [J].

Chung, Christine H. .

ONCOLOGIST, 2008, 13 (06) :725-732

[6]

D'Arcy CA, 2001, ARTHRITIS RHEUM, V44, P1717, DOI 10.1002/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO

[7]

2-C

[8] Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide [J].

Dimopoulos, Meletios Athanasios ;

Anagnostopoulos, Athanasios ;

Kyrtsonis, Marie-Christine ;

Zervas, Konstantinos ;

Tsatalas, Constantinos ;

Kokkinis, Garyfallia ;

Repoussis, Panagiotis ;

Symeonidis, Argyris ;

Delimpasi, Souzana ;

Katodritou, Eirini ;

Vervessou, Elina ;

Michali, Evridiki ;

Pouli, Anastasia ;

Gika, Dimitra ;

Vassou, Amalia ;

Terpos, Evangelos ;

Anagnostopoulos, Nikolaos ;

Economopoulos, Theophanis ;

Pangalis, Gerasimos .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3344-3349

[9] Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia [J].

Finger, Eduardo ;

Scheinberg, Morton .

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2007, 13 (02) :94-95

[10] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group [J].

Fischer, Kirsten ;

Cramer, Paula ;

Busch, Raymonde ;

Stilgenbauer, Stephan ;

Bahlo, Jasmin ;

Schweighofer, Carmen D. ;

Boettcher, Sebastian ;

Staib, Peter ;

Kiehl, Michael ;

Eckart, Michael J. ;

Kranz, Gabriele ;

Goede, Valentin ;

Elter, Thomas ;

Buehler, Andreas ;

Winkler, Dirk ;

Kneba, Michael ;

Doehner, Hartmut ;

Eichhorst, Barbara F. ;

Hallek, Michael ;

Wendtner, Clemens-Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) :3559-3566

← 1 2 3 →